Is there a role for pembrolizumab beyond progression in urothelial carcinoma?

Affiliations

¹ Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
² Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.

Editorial

Satoru Taguchi et al. BJU Int. 2024 Jul.

. 2024 Jul;134(1):43-44.

doi: 10.1111/bju.16245. Epub 2023 Dec 18.

¹ Department of Urology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
² Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan.

No abstract available

Comment on

Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
Topp BG, Channavazzala M, Mayawala K, De Alwis DP, Rubin E, Snyder A, Wolchok JD, Ribas A. Topp BG, et al. Cancer Cell. 2023 Sep 11;41(9):1680-1688.e2. doi: 10.1016/j.ccell.2023.08.004. Cancer Cell. 2023. PMID: 37699333 Free PMC article.

1. Topp BG, Channavazzala M, Mayawala K et al. Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression. Cancer Cell 2023; 41: 1680–1688.e2
1. Necchi A, Joseph RW, Loriot Y et al. Atezolizumab in platinum‐treated locally advanced or metastatic urothelial carcinoma: post‐progression outcomes from the phase II IMvigor210 study. Ann Oncol 2017; 28: 3044–3050
1. Bersanelli M, Buti S, Cortellini A et al. Clinical outcomes of patients with metastatic urothelial carcinoma after progression to immune checkpoint inhibitors: a retrospective analysis by the meet‐URO group (meet‐URO 1 study). Clin Med Insights Oncol 2021; 15: 11795549211021667
1. Fukuokaya W, Kimura T, Yanagisawa T et al. Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma. Cancer Immunol Immunother 2022; 71: 229–236
1. Kita Y, Ito K, Sano T et al. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre‐enfortumab vedotin era. Int J Urol 2022; 29: 647–655